Samsung Biologics Collaborates with Dinona to Develop DNP-019 for COVID-19

 Samsung Biologics Collaborates with Dinona to Develop DNP-019 for COVID-19

Samsung Biologics Collaborates with Dinona to Develop DNP-019 for COVID-19

Shots:

  • The companies collaborate for fast-track development of DNP-019 against COVID-19
  • The collaboration will expand Samsung’s CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing
  • Samsung has introduced its proprietary cell-line technology, S-CHOice, demonstrating improved titers up to two-fold and maintaining over 90% cell viability

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post